保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Recurso digital |
| 言語: | |
| 出版事項: |
Zenodo
2025
|
| オンライン･アクセス: | https://doi.org/10.5281/zenodo.17963802 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
目次:
- <p><span lang="EN-US">In‑vitro bioassays are a critical bridge between the traditional use of herbal medicines and their modern development as evidence‑based products. They provide controlled, mechanistic data on efficacy, safety, and mode of action before escalation to animal or clinical studies, which is essential for complex botanical mixtures with multi‑target activity. The MTT assay remains a workhorse for quantifying cytotoxicity and anticancer potential of herbal extracts, enabling calculation of IC50 values, comparison of selectivity between tumour and normal cells, and kinetic assessment of cytostatic versus cytotoxic effects. Complementing this, ELISA‑based quantification of cytokines and oxidative stress–related markers offers high‑specificity insight into how herbal products modulate inflammatory pathways, cytokine storms, and redox signalling. The comet assay adds a highly sensitive layer of genotoxic evaluation by resolving DNA strand breaks and repair kinetics at the single‑cell level, clarifying whether botanicals exert protective antioxidant actions or induce potentially harmful DNA damage. Indirect immunofluorescence provides spatially resolved evidence for protein localisation and trafficking, such as nuclear translocation of transcription factors, changes in apoptosis markers, and alterations in cytoskeletal or adhesion proteins that underpin anticancer and anti‑metastatic claims. When these assays are implemented within an integrated, validated in‑vitro platform, herbal product companies can assemble coherent biological dossiers that support mechanism‑anchored claims, guide lead selection and formulation, and satisfy emerging regulatory expectations for robust in‑vitro evidence in herbal drug and nutraceutical development.</span></p>